|
|
Article: Phase III: reloxin shows rapid onset, lasting effect.(Dermatologic Surgery)
- Article from:
- Skin & Allergy News
- Article date:
- December 1, 2005
- Author:
-
|
Copyright informationCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ATLANTA -- Recently completed phase III data on Reloxin, a botulinum toxin type A formulation known as Dysport in Europe, may hasten the product's availability in the United States, Gary Monheit, M.D., said at the annual meeting of the American Society for Dermatologic Surgery and the American College of Mohs Micrographic Surgery and Cutaneous Oncology.
The new data on this "other Botox" have not been released, but Dr. Monheit described his experience with patients involved in the trial.
In a phase II trial in the United States, Reloxin was shown to be safe and effective at 30 days' follow-up. The phase III trial included 300 patients and tracked safety and efficacy ...
Related newspaper, magazine, and journal articles:
|
|
Article: Lasers, ultrasound expand in diverse directions.(Dermatologic Surgery)
Skin & Allergy News;
December 1, 2005 ;
606 words
......Va.), the first LED approved in the United States for the treatment of periorbital wrinkles...Palo Alto, Calif.) was approved in the United States in late July for the treatment of melasma...study of more than 300 people in the United States, United Kingdom, Japan, and Israel...
|
|